Free Trial
NASDAQ:EVOK

Evoke Pharma Q1 2023 Earnings Report

Evoke Pharma logo
$4.43 -0.16 (-3.49%)
Closing price 04:00 PM Eastern
Extended Trading
$4.56 +0.13 (+2.93%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evoke Pharma EPS Results

Actual EPS
-$8.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$0.81 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Monday, May 15, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Evoke Pharma's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Evoke Pharma Earnings Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat